A new AI-powered risk prediction model assists clinicians in treating cancer patients following a heart attack by combining oncology and cardiovascular data.
Key Details
- 1Researchers at University of Zurich developed ONCO-ACS, an AI-based tool for individualized risk assessment in cancer patients post-heart attack.
- 2Used data from over 1 million heart attack patients, including 47,000 with cancer, from England, Sweden, and Switzerland.
- 3Cancer patients showed a nearly 1 in 3 mortality rate within six months after a heart attack.
- 4ONCO-ACS predicts risks of death, major bleeding, or recurrent cardiac event within six months, using both cancer-related and standard cardiovascular data.
- 5The tool is validated and aims to support tailored decisions regarding catheter-based interventions and antiplatelet therapy.
Why It Matters
This is among the first AI tools designed specifically for the intersection of oncology and cardiology, addressing a major gap in risk prediction for a previously overlooked patient population. It could improve outcomes and inform personalized care strategies in radiology and broader clinical management.
Source
EurekAlert
Related News
•EurekAlert
FDA Approves Johns Hopkins AI Tool for Early Sepsis Detection
FDA clears an AI-driven system developed by Johns Hopkins to detect sepsis up to 48 hours earlier and reduce mortality rates.
•EurekAlert
New AI Vision-Language Model Enhances Chest CT Diagnostics
Researchers developed an interpretable AI model that uses visual question answering to generate detailed diagnostic findings from chest CT scans, aimed at improving lung cancer diagnosis.
•EurekAlert
Optical AI Chip Boosts Real-Time Dry Eye Gland Diagnosis Accuracy
A new metasurface spectral AI chip enables rapid, accurate diagnosis of meibomian gland dysfunction (MGD) from tissue samples, achieving 96.22% accuracy.